3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Conditions
Infections
3
Febrile Neutropenia
3
Neutropenia
2
Neoplasms
2
Fever
2
Waldenstrom Macroglobulinemia
1
Urinary Tract Infections
1
Stomach Neoplasms
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Recurrence
1
Pulmonary Arterial Hypertension
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia
1
Pain
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Migraine Disorders
1
Menorrhagia
1
Meningitis, Bacterial
1
Interventions
Gemcitabine
74
Capecitabine
60
Paclitaxel
59
Fluorouracil
58
Oxaliplatin
57
Bevacizumab
51
Docetaxel
50
Leucovorin
48
Nivolumab
40
Cisplatin
40
Irinotecan
39
Carboplatin
37
Cetuximab
33
pembrolizumab
32
Radiosurgery
32
Trastuzumab
30
Radiotherapy
27
Everolimus
24
Sorafenib
23
Pemetrexed
20
Doxorubicin
20
Albumin-Bound Paclitaxel
20
Ipilimumab
19
Cyclophosphamide
19
Panitumumab
18
Zoledronic Acid
17
Lapatinib
17
Erlotinib Hydrochloride
17
Prednisone
16
pazopanib
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasm Metastasis
×
Vancomycin
×
Clear all
NCT04208958
2025-10-27
ConsortiumIO
Vedanta Biosciences, Inc.
Phase 1/2
Completed
56 enrolled
11 charts